Paratek Pharmaceuticals Receives New Coverage from Analysts at StockNews.com

About 67% of Paratek Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Paratek Pharmaceuticals suggests that many traders are alarmed regarding Paratek Pharmaceuticals' prospects. Paratek Pharmaceuticals' investing sentiment shows overall attitude of investors towards Paratek Pharmaceuticals.
  
StockNews.com began coverage on shares of Paratek Pharmaceuticals in a research report released on Thursday morning. The firm issued a hold rating on the specialty pharmaceutical companys stock. Other equities research analysts have also recently issued research reports about the company. HC Wainwright restated a neutral rating and issued a 2.15

Read at thelincolnianonline.com
news
  

Paratek Pharmaceuticals Fundamental Analysis

We analyze Paratek Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Paratek Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Paratek Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Total Asset

Total Asset Comparative Analysis

Paratek Pharmaceuticals is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.

Paratek Pharmaceuticals Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Paratek Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Paratek Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Paratek Pharmaceuticals by comparing valuation metrics with similar companies.

Peers

Paratek Pharmaceuticals Related Equities

LYRALyra Therapeutics   5.00   
0%
100.0%
JSPRJasper Therapeutics   4.59   
0%
91.0%
CRVSCorvus Pharmaceuticals   2.54   
0%
50.0%
HOOKHookipa Pharma   2.00   
0%
40.0%
IMMPImmutep   1.58   
0%
31.0%
AFMDAffimed NV   0.96   
19.0%
0%
EQEquillium   1.30   
26.0%
0%
ADAPAdaptimmune Therapeutics   1.82   
36.0%
0%
APTOAptose Biosciences   1.85   
37.0%
0%
LPTXLeap Therapeutics   4.17   
83.0%
0%
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Other Consideration for investing in Paratek Stock

If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Stocks Directory
Find actively traded stocks across global markets
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Fundamental Analysis
View fundamental data based on most recent published financial statements
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance